What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Nivolumab shows moderate benefit over current care, with a median overall survival of 7.7 months compared to 5.1 months for the investigator’s choice treatment. However, the clinical effectiveness compared to docetaxel remains uncertain due to the small sample size of the subgroup analysis and the potential bias from treatment switching.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for nivolumab are likely within the acceptable range for Healthcare resources, especially considering it meets the criteria for life-extending treatment at the end of life. The committee concluded that the ICER would be substantially below £50,000 per QALY gained.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests that nivolumab may improve quality of life for patients with recurrent or metastatic SCCHN, as indicated by patient expert testimonies. However, the exact impact on HRQoL is not quantified in the document, leading to a moderate rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Nivolumab has a very good safety profile with mostly mild or moderate adverse events reported. The committee noted that serious adverse reactions are associated with existing treatments, indicating that nivolumab is likely to be better tolerated.
Was the drug compared against what payers expect? — Comparator Selection
The committee identified docetaxel as the most appropriate comparator for nivolumab, and the evidence from the CheckMate 141 trial provides a relevant comparison, despite some limitations in the trial design.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is considered moderately representative of the intended patient population, with some subgroup analyses provided. However, there are concerns about the generalizability of the results to the broader Healthcare population.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Nivolumab can be integrated into existing care pathways with minor adjustments, as it does not require new infrastructure or extensive training for healthcare professionals.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of nivolumab is manageable, and the treatment is expected to be resource-efficient, particularly with the commercial access agreement in place.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a robust Phase III RCT (CheckMate 141) and additional real-world data from the SACT dataset, although there are some methodological concerns.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there is some uncertainty regarding the clinical effectiveness and cost-effectiveness estimates, the context of unmet need and the potential benefits of nivolumab support its use.
